---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-023439"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2026-03-04T23:59:59+00:00"
generated_at: "2026-05-15T21:38:52.644802+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Citius subsidiary reports Phase 1 data: LYMPHIR + CAR-T shows 86% ORR, 57% CR in high-risk DLBCL

## Summary
- ORR 86% at 1 month (57% CR, 29% PR) in 14 patients with relapsed/refractory DLBCL.
- One-year PFS 77% (95% CI: 43–92%); one-year OS 84% (95% CI: 49–96%).
- Well-tolerated: no dose-limiting toxicities, no Grade≥3 LYMPHIR-related immune AEs.
- Single LYMPHIR dose depleted circulating Tregs (median reduction 24 Tregs/µL).
- Study conducted at Univ of Minnesota and City of Hope; presented at 2026 Tandem Meetings.

## SEC filing metadata
- accession: 0001213900-26-023439
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2026-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390026023439/0001213900-26-023439-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390026023439/ea0277422-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-023439
- JSON: https://secwatch.observer/filing/0001213900-26-023439.json
- Plain text: https://secwatch.observer/filing/0001213900-26-023439.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.